Trop2 antibody or antigen-binding fragment thereof and application thereof
By designing specific Trop2 binding molecules and chimeric antigen receptors, the safety and efficiency of existing Trop2-targeted therapies are solved, effective killing of Trop2-highly expressed cancer cells, and significantly improving the therapeutic effect of CAR-T cells and security.
Patent Information
- Application Number
- CN202410947698.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-16
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-07-16
AI Technical Summary
The existing Trop2 targeted therapies have safety and efficiency problems, especially due to the human anti-mouse antibody response caused by murine-derived antibodies, which leads to the removal of CAR-T cells in the circulatory system, losing their efficacy, and making it difficult to develop good therapeutic effects and Safe Trop2 binding molecule.
Provided a Trop2 binding molecule, comprising an anti-Trop2 antibody or antigen binding fragment thereof, including specific heavy and light chain variable region sequences, for the construction of chimeric antigen receptors (CARs) to improve specific recognition of Trop2 and lethality.
The constructed Trop2 CAR-T cells have significant killing effects on breast cancer cells with high expression of Trop2, and have good targeted therapeutic effects and safety, which is better than CAR-T cells constructed by traditional Trop2 antibodies.
Smart Images

Figure CN118496368B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to a Trop2 antibody or an antigen-binding fragment thereof and applications thereof. Background Art
[0002] Traditional surgical resection, chemotherapy, and radiotherapy for tumors are harmful to normal tissues, have limitations, and have limited effects. Targeted therapies that have emerged in recent years design corresponding therapeutic drugs for the identified carcinogenic sites at the cellular and molecular levels. When the drugs enter the body, they will specifically select the carcinogenic sites to combine and act, causing tumor cells to die specifically without harming the normal tissue cells around the tumor.
[0003] Trop2 is a cell surface glycoprotein encoded and expressed by the TACSTD2 gene, and its full name is Trophoblast Cell Surface Antigens 2. Trop2 consists of a hydrophobic leader peptide, an extracellular domain, a transmembrane domain, and a cytoplasmic tail. It is a single transmembrane glycoprotein with a size of 35.7KD and is a type of calcium channel signal converter. The N-terminus of the Trop2 protein is an extracellular domain (Trop2 EC), which is connected to the intracellular short tail (Trop2 IC) through a unidirectional transmembrane helix (TM) to be fixed to the cell membrane. Its cytoplasmic tail has a highly conserved phosphatidylinositol 4,5-bisphosphate (PIP2) binding sequence, indicating that PIP2 plays an important role in Trop2 signal transduction. In addition to the PIP2 binding motif, it also contains conserved tyrosine and serine phosphorylation sites. Trop2 is not expressed or expressed at a low level in normal tissues, but is overexpressed in many malignant tumors such as breast cancer, gastric cancer, colorectal cancer, pancreatic cancer, prostate cancer, cervical cancer, head and neck cancer, and ovarian cancer. It can promote the occurrence, invasion, metastasis, and spread of tumors, and plays a key role in the tumor growth process. Therefore, Trop2 is considered to be a candidate target for tumor immunity.
[0004] Chimeric Antigen Receptor-T cell (CAR-T) T cells refer to genetically modified T cells that can recognize specific target antigens in an MHC-unrestricted manner and continuously activate and proliferate. The 2012 International Society of Cell Therapy Annual Meeting pointed out that biological immune cell therapy has become the fourth means of treating tumors in addition to surgery, radiotherapy, and chemotherapy. It is a new immunotherapy method targeting specific antigens on the surface of tumor cells. A large number of studies have shown that CAR-T cells can effectively recognize tumor antigens, induce specific anti-tumor immune responses, and significantly improve the survival of patients.
[0005] Chimeric antigen receptor (CAR) is the core component of CAR-T, which gives T cells the ability to recognize tumor antigens in an HLA-independent manner, which enables CAR-modified T cells to recognize a wider range of targets compared to natural T cell surface receptors TCR. The basic design of CAR includes a tumor-associated antigen (TAA) binding region (usually derived from the scFv segment of the monoclonal antibody antigen binding region), an extracellular hinge region, a transmembrane region and an intracellular signaling domain. The choice of target antigen is a key determinant of the specificity and effectiveness of CAR and the safety of the genetically modified T cells themselves.
[0006] Single-chain antibodies are an important component of CAR. Traditionally, mouse antibodies are used. However, due to the heterogeneity of mouse antibodies, they can cause human anti-mouse antibody reaction (HAMA), which can cause CAR-T to be quickly cleared from the circulatory system and lose its efficacy.
[0007] Currently, there is a need to develop more Trop2-binding molecules with good therapeutic efficacy and safety to treat Trop2-mediated diseases more safely and efficiently. Summary of the invention
[0008] The present invention provides a Trop2 binding molecule, which comprises an anti-Trop2 antibody or an antigen-binding fragment thereof, wherein the Trop2 binding molecule comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a heavy chain complementary determining region HCDR as shown in any one of SEQ ID NOs: 1-3, 7-9, 13-15, and 19-21, and the light chain variable region comprises a light chain complementary determining region LCDR as shown in any one of SEQ ID NOs: 4-6, 10-12, 16-18, and 22-24,
[0009] In one or more embodiments, the CDR sequence of the heavy chain variable region and the CDR sequence of the light chain variable region are selected from any one of the following:
[0010] (1) HCDR1 with the sequence shown in SEQ ID NO:1, HCDR2 with the sequence shown in SEQ ID NO:2, HCDR3 with the sequence shown in SEQ ID NO:3, LCDR1 with the sequence shown in SEQ ID NO:4, LCDR2 with the sequence shown in SEQ ID NO:5, and LCDR3 with the sequence shown in SEQ ID NO:6;
[0011] (2) HCDR1 with the sequence shown in SEQ ID NO:7, HCDR2 with the sequence shown in SEQ ID NO:8, HCDR3 with the sequence shown in SEQ ID NO:9, LCDR1 with the sequence shown in SEQ ID NO:10, LCDR2 with the sequence shown in SEQ ID NO:11, and LCDR3 with the sequence shown in SEQ ID NO:12;
[0012] (3) HCDR1 with a sequence as shown in SEQ ID NO:13, HCDR2 with a sequence as shown in SEQ ID NO:14, HCDR3 with a sequence as shown in SEQ ID NO:15, LCDR1 with a sequence as shown in SEQ ID NO:16, LCDR2 with a sequence as shown in SEQ ID NO:17, and LCDR3 with a sequence as shown in SEQ ID NO:18;
[0013] (4) HCDR1 with the sequence shown in SEQ ID NO: 19, HCDR2 with the sequence shown in SEQ ID NO: 20, HCDR3 with the sequence shown in SEQ ID NO: 21, LCDR1 with the sequence shown in SEQ ID NO: 22, LCDR2 with the sequence shown in SEQ ID NO: 23, and LCDR3 with the sequence shown in SEQ ID NO: 24.
[0014] In one or more embodiments, the amino acid sequence of the heavy chain variable region is shown in any one of SEQ ID NOs: 25, 27, 29 and 31; the amino acid sequence of the light chain variable region is shown in any one of SEQ ID NOs: 26, 28, 30 and 32;
[0015] In one or more embodiments, the sequences of the heavy chain variable region and the light chain variable region are selected from any one of the following:
[0016] (1) When the amino acid sequence of the heavy chain variable region is as shown in SEQ ID NO: 25, the amino acid sequence of the light chain variable region is as shown in SEQ ID NO: 26;
[0017] (2) when the amino acid sequence of the heavy chain variable region is as shown in SEQ ID NO: 27, the amino acid sequence of the light chain variable region is as shown in SEQ ID NO: 28;
[0018] (3) when the amino acid sequence of the heavy chain variable region is as shown in SEQ ID NO:29, the amino acid sequence of the light chain variable region is as shown in SEQ ID NO:30;
[0019] (4) When the amino acid sequence of the heavy chain variable region is as shown in SEQ ID NO:31, the amino acid sequence of the light chain variable region is as shown in SEQ ID NO:32.
[0020] In one or more embodiments, the antibody is at least one of a monoclonal antibody, a humanized antibody, a chimeric antibody, and a bispecific antibody; and the antigen-binding fragment is at least one of Fab, F(ab'), F(ab')2, a single-chain antibody scFv, or a disulfide-linked Fv (sdFv).
[0021] Another aspect of the present invention provides a chimeric antigen receptor comprising an optional signal peptide sequence, the Trop2 binding molecule described in any embodiment herein, a hinge region, a transmembrane region and an intracellular region.
[0022] In one or more embodiments, the intracellular region includes an intracellular co-stimulatory domain and / or an intracellular signaling domain.
[0023] In one or more embodiments, the chimeric antigen receptor comprises, from N-terminus to C-terminus, a signal peptide, a Trop2 binding molecule as described in any embodiment herein, a hinge region, a transmembrane region, an intracellular co-stimulatory domain and an intracellular signaling domain.
[0024] The present invention also provides a nucleic acid molecule having a sequence selected from any one of the following:
[0025] (1) the coding sequence of the Trop2 binding molecule or chimeric antigen receptor described in any embodiment of the present invention;
[0026] (2) The complementary sequence of (1).
[0027] In one or more embodiments, the fragment is a primer.
[0028] The present invention also provides a nucleic acid construct comprising the nucleic acid molecule described herein.
[0029] In one or more embodiments, the nucleic acid construct is a cloning vector, an expression vector, or an integration vector.
[0030] The present invention also provides a host cell selected from:
[0031] (1) expressing and / or secreting the Trop2 binding molecule or chimeric antigen receptor described in any embodiment of the present invention;
[0032] (2) comprising a nucleic acid molecule as described herein; and / or
[0033] (3) comprising the nucleic acid construct described herein.
[0034] In one or more embodiments, the host cell is an immune effector cell, preferably a T cell.
[0035] The present invention also provides a method for producing a Trop2-binding molecule of any embodiment herein, comprising: culturing the host cell described herein under conditions suitable for producing a Trop2-binding molecule (e.g., an anti-Trop2 antibody or an antigen-binding fragment thereof, a monovalent or multivalent anti-Trop2 antibody, or a multispecific anti-Trop2 antibody), and optionally purifying the Trop2-binding molecule from the culture.
[0036] The present invention also provides a pharmaceutical composition comprising the Trop2 binding molecule, nucleic acid molecule, nucleic acid construct or host cell described in any embodiment of the present invention, and a pharmaceutically acceptable excipient.
[0037] In one or more embodiments, the pharmaceutical composition is used to treat a disease or condition associated with Trop2 expression.
[0038] The present invention also provides use of the Trop2 binding molecule, chimeric antigen receptor, nucleic acid molecule, nucleic acid construct or host cell described in any embodiment herein in preparing activated immune cells (eg, T cells).
[0039] The present invention also provides use of the Trop2 binding molecule, chimeric antigen receptor, nucleic acid molecule, nucleic acid construct or host cell described in any embodiment herein in the preparation of a medicament for preventing or treating a disease or condition associated with Trop2 expression.
[0040] In one or more embodiments, the disease or condition is selected from one or more of the following: breast cancer, gastric cancer, colorectal cancer, pancreatic cancer, prostate cancer, cervical cancer, head and neck cancer, lung cancer, esophageal cancer, kidney cancer, bladder cancer, uterine cancer and ovarian cancer.
[0041] The present invention also provides a method for treating or preventing a disease or condition associated with Trop2 expression, the method comprising administering to a patient in need thereof a therapeutically effective amount of the Trop2 binding molecule or host cell according to any embodiment of the present invention, or the pharmaceutical composition according to any embodiment of the present invention.
[0042] The present invention also provides a kit for detecting Trop2, which is used, for example, to evaluate the effect of drug treatment or diagnose cancer, and the kit comprises the Trop2 binding molecule, nucleic acid molecule, nucleic acid construct or host cell described in any embodiment of the present invention.
[0043] In one or more embodiments, the kit further comprises a reagent for detecting the binding of Trop2 to the Trop2 binding molecule, for example, a reagent for detecting the binding by enzyme-linked immunosorbent assay.
[0044] In one or more embodiments, the reagent for detecting binding is a detectable label that can be linked to the Trop2 binding molecule, such as biotin. The detectable label is linked to the Trop2 binding molecule or exists separately in the kit.
[0045] The present invention also provides a non-diagnostic method for detecting the presence of Trop2 in a sample, the method comprising: incubating the sample with the Trop2 binding molecule described in any embodiment of the present invention, and detecting the binding of Trop2 to the Trop2 binding molecule, thereby determining the presence of Trop2 in the sample. The detection is an enzyme-linked immunosorbent assay.
[0046] The present invention also provides use of the Trop2 binding molecule described in any embodiment herein in preparing a kit for detecting Trop2 in a sample, evaluating the effect of drug treatment or diagnosing cancer.
[0047] The present invention has the following beneficial effects:
[0048] The present invention provides an antibody that specifically recognizes Trop2 and a CAR-modified cell containing the antibody. The antibody and the cell have good therapeutic effect and safety in targeting Trop2. The constructed Trop2 CAR-T cells have an outstanding killing effect on breast cancer cells, especially breast cancer cells that highly express Trop2, and are significantly superior to other Trop2 antibodies screened in the same period and CAR-T cells constructed from other known Trop2 antibodies. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0050] Figure 1 This is the SDS electrophoresis diagram of the recombinant human Trop2-avi-his antigen protein.
[0051] Figure 2 The figure is the SDS-PAGE picture of antibody proteins of different clones.
[0052] Figure 3 ELISA diagram of the binding of antibodies of different clones to Trop2 antigen.
[0053] Figure 4 Schematic diagram of the structure of different cloned CARs.
[0054] Figure 5The tonic signal flow cytometry images of different clones.
[0055] Figure 6 This is the expression of CAR positivity rate of Trop2 CAR-T cells of different clones.
[0056] Figure 7 is the expression of Trop2 on the surface of target cells.
[0057] Figure 8 These are the results of the killing experiment of different clones of Trop2 CAR-T cells on positive target cells MDA-MB-231 and control target cells MDA-MB-231-Trop2KO.
[0058] Fig. 9 These are the results of the killing experiment of different clones of Trop2 CAR-T cells on positive target cells MDA-MB-468 and control target cells MDA-MB-468-Trop2KO.
[0059] Fig.10 The results of the killing experiment of different clones of Trop2 CAR-T cells on Trop2-overexpressing HCC1395 and control target cells HCC1395.
[0060] Fig.11 The results of the killing experiment of L3F4 Trop2 CAR-T cells and control T cells on HCC1395 overexpressing Trop2. DETAILED DESCRIPTION
[0061] The present inventors have conducted extensive and in-depth research and found, after a large number of screenings, a class of anti-Trop2 antibodies and antigen-binding fragments thereof, which can specifically recognize Trop2, bind to Trop2 with high affinity, and have good functional activity.
[0062] Specifically, the present invention first constructs a human Trop2 protein expression vector, expresses and purifies the human Trop2 protein in eukaryotic cells, then constructs a human natural antibody phage display library, and selects anti-Trop2 antibodies with good targeting and safety that can specifically bind to the extracellular domain of human Trop2.
[0063] The present invention also provides a chimeric antigen receptor (CAR) containing the anti-Trop2 antibody. The vector containing the coding sequence of the CAR is used to infect immune cells, and immune effector cells with significant killing ability against tumor cells overexpressing Trop2 can be obtained. The immune effector cells can be used to treat or improve diseases related to Trop2 expression, especially the killing effect on HCC1395 overexpressing Trop2 is very significant.
[0064] Antibody
[0065] Herein, "Trop2 binding molecules" are proteins that specifically bind to Trop2, including but not limited to antibodies, heavy chain antibodies, nanobodies or antigen-binding fragments thereof.
[0066] Herein, the term "antibody" includes monoclonal antibodies (including full-length antibodies, which have an immunoglobulin Fc region), antibody compositions with multiple epitope specificities, multispecific antibodies (e.g., bispecific antibodies), diabodies and single-chain molecules, as well as antibody fragments, especially antigen-binding fragments, such as Fab, F(ab')2, Fd and Fv. Herein, "antibody" and "immunoglobulin" are used interchangeably.
[0067] Traditional "antibodies" contain a basic 4-chain antibody unit, which is a heterotetrameric glycoprotein composed of two identical light chains (L) and two identical heavy chains (H). Each heavy chain has a variable domain (VH) at the N-terminus, followed by three (CH1, CH2 and CH3 for each α and γ chain) and four (CH1, CH2, CH3 and CH4 for μ and ε isotypes) constant domains (CH) and a hinge region (Hinge) between the CH1 domain and the CH2 domain. Each light chain has a variable domain (VL) at the N-terminus, followed by a constant domain (CL) at its other end. Pairs of VH and VL together form an antigen binding site. For the structure and properties of different classes of antibodies, see, for example, Basic and Clinical Immunology, 8th edition, Daniel P. Sties, Abba I. Terr and Tristram G. Parsolw, eds., Appleton & Lange, Norwalk, CT, 1994, p. 71 and Chapter 6. Light chains from any vertebrate species can be assigned to one of two distinct types, called kappa and lambda, based on their constant domain amino acid sequences. The gamma and alpha classes can be further divided into subclasses based on relatively minor differences in CH sequence and function, for example humans express the following subclasses: IgG1, IgG2A, IgG2B, IgG3, IgG4, IgA1, and IgA2.
[0068] The "variable region" or "variable domain" of an antibody refers to the amino terminal domain of the heavy or light chain of an antibody. The variable domains of the heavy and light chains may be referred to as "VH" and "VL", respectively. These domains are generally the most variable parts of an antibody (relative to other antibodies of the same type) and contain the antigen binding site.
[0069] The term "variable" refers to the situation where certain segments in the variable domain vary widely in the antibody sequence. The variable domain mediates antigen binding and defines the specificity of a particular antibody for its specific antigen. However, the variability is not evenly distributed across all the amino acids spanned by the variable domain. Instead, it is concentrated in three segments called hypervariable regions (HVRs) (in both the light chain and heavy chain variable domains), namely HCDR1, HCDR2, HCDR3 of the heavy chain variable domain and LCDR1, LCDR2 and LCDR3 of the light chain variable domain. The more highly conserved parts of the variable domain are called framework regions (FRs). The variable domains of natural heavy and light chains each contain four FR regions (FR1, FR2, FR3 and FR4), most of which adopt a β-sheet conformation and are connected by three HVRs that form a loop connection and in some cases form part of the β-sheet structure. The HVRs in each chain are kept together very closely by the FR regions and contribute to the formation of the antigen binding site of the antibody together with the HVRs of the other chain. Typically, the structure of the light chain variable region is FR1-LCDR1-FR2-LCDR2-FR3-LCDR3-FR4, and the structure of the heavy chain variable region is FR1-HCDR1-FR2-HCDR2-FR3-HCDR3-FR4. The constant domain is not directly involved in the binding of the antibody to the antigen, but exhibits a variety of effector functions, such as the participation of the antibody in antibody-dependent cell-mediated cytotoxicity. There are multiple annotation schemes for the variable region of the antibody, including: Chothia, Kabat, IMGT and Contact. The IMGT annotation scheme is used as an example herein.
[0070] "Fc region" (fragment crystallizable region) or "Fc domain" or "Fc" refers to the C-terminal region of an antibody heavy chain that mediates the binding of an immunoglobulin to host tissues or factors, including binding to Fc receptors located on various cells of the immune system (e.g., effector cells), or binding to the first component (C1q) of the classical complement system. In IgG, IgA, and IgD antibody isotypes, the Fc region is composed of two identical protein fragments from the CH2 domain and the CH3 domain of the two heavy chains of the antibody; the Fc region of IgM and IgE contains three heavy chain constant domains (CH domains 2-4) in each polypeptide chain. Although the boundaries of the Fc region of an immunoglobulin heavy chain can vary, the human IgG heavy chain Fc region is generally defined as a sequence segment from an amino acid residue at position C226 or P230 of the heavy chain to the carboxyl terminus, wherein the numbering is according to the EU index, as in Kabat. As used herein, the Fc region may be a native sequence Fc or a variant Fc.
[0071] "Antibody fragments" comprise a portion of an intact antibody, preferably the antigen binding region and / or variable region of an intact antibody. Antibody fragments are preferably antigen binding fragments of antibodies. Examples of antibody fragments include Fab, Fab', F(ab'), F(ab')2, Fd, and Fv fragments, disulfide-linked Fv; diabodies; linear antibodies; single-chain antibody molecules; scFv-Fc fragments; multispecific antibodies formed from antibody fragments; and any fragments that should be able to increase half-life by chemical modification or by incorporation into liposomes. Antigen binding fragments can be prepared by a variety of techniques, including but not limited to proteolytic digestion of intact antibodies, and expression by host cells containing antigen binding fragments.
[0072] "Fv" is the smallest antibody fragment that contains a complete antigen recognition and binding site. The fragment consists of a dimer of one heavy chain variable domain and one light chain variable domain in tight, non-covalent association. From the folding of these two domains protrude six hypervariable loops (3 loops each from the heavy and light chains) that contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody. However, even a single variable domain (or half an Fv containing only three HVRs specific for an antigen) has the ability to recognize and bind antigen, albeit with less affinity than the complete binding site. "Single-chain Fv", also abbreviated as "sFv" or "scFv", is an antibody fragment comprising the antibody VH and VL domains connected into one polypeptide chain. Preferably, the sFv polypeptide also contains a polypeptide linker between the VH and VL domains so that the sFv forms the desired antigen binding structure.
[0073] Herein, the term "monoclonal antibody" refers to an antibody obtained from a group of substantially homogeneous antibodies, that is, except for possible natural mutations and / or post-translational modifications (such as isomerization, amidation) that may exist in a small amount, each antibody constituting the group is identical.Monoclonal antibodies are highly specific and are directed to a single antigenic site.Compared with polyclonal antibody preparations (which typically include different antibodies directed to different determinants (epitopes)), each monoclonal antibody is directed to a single determinant on the antigen.Except for their specificity, the advantage of monoclonal antibodies is that they are synthesized by hybridoma culture without being contaminated by other immunoglobulins.The modifier "monoclonal" indicates that the antibody is obtained from a substantially homogeneous antibody group and should not be interpreted as requiring the production of antibodies by any ad hoc method.For example, the monoclonal antibody used according to the present invention can be generated by a variety of techniques, including, for example, hybridoma method, phage display method, recombinant DNA method, and technology, single cell sequencing method for generating human or human-like antibodies from animals with part or all of the human immunoglobulin locus or genes encoding human immunoglobulin sequences.
[0074] Monoclonal antibodies herein also include "chimeric" antibodies in which a portion of the heavy and / or light chain is identical or homologous to the corresponding sequence in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical or homologous to the corresponding sequence in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity.
[0075] The "humanized" form of a non-human (e.g., mouse) antibody refers to a chimeric antibody that contains at least a sequence derived from a non-human immunoglobulin. Therefore, a "humanized antibody" generally refers to a non-human antibody in which the variable domain framework region is exchanged with a sequence found in a human antibody. Typically in a humanized antibody, the entire antibody (except for the CDR) is encoded by a polynucleotide of human origin or is identical to such an antibody (except for the CDR). The CDRs (some or all of which are encoded by nucleic acids derived from non-human organisms) are transplanted into the β-folded framework of the variable region of a human antibody to produce an antibody, the specificity of which is determined by the transplanted CDR. The production methods of such antibodies are well known in the art, for example, using mice with a genetically engineered immune system. In the present invention, antibodies, single-chain antibodies, etc. all include humanized variants of each of the antibodies.
[0076] "Human antibody" refers to an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody produced by a human and / or produced using any of the techniques disclosed herein for producing human antibodies. This definition of human antibody explicitly excludes humanized antibodies comprising non-human antigen-binding residues. Human antibodies can be produced using a variety of techniques known in the art, including phage display libraries.
[0077] In some embodiments, the present invention also provides an antibody or an antigen-binding fragment thereof that binds to the same epitope on human Trop2 as the antigen-binding region of any anti-Trop2 antibody of the present invention, that is, an antibody or an antigen-binding fragment thereof that can cross-compete with the antigen-binding region of any antibody of the present invention for binding to Trop2.
[0078] In the present invention, the Trop2 binding molecule includes a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region includes a heavy chain complementary determining region HCDR shown in any one of SEQ ID NOs: 1-3, 7-9, 13-15, 19-21, and the light chain variable region includes a light chain complementary determining region LCDR shown in any one of SEQ ID NOs: 4-6, 10-12, 16-18, 22-24. Preferably, the CDR sequence of the heavy chain variable region and the CDR sequence of the light chain variable region of the Trop2 binding molecule of the present invention are selected from any of the following: (a) HCDR1 with a sequence as shown in SEQ ID NO:1, HCDR2 with a sequence as shown in SEQ ID NO:2, HCDR3 with a sequence as shown in SEQ ID NO:3, and LCDR1 with a sequence as shown in SEQ ID NO:4, LCDR2 with a sequence as shown in SEQ ID NO:5, and LCDR3 with a sequence as shown in SEQ ID NO:6; (b) HCDR1 with a sequence as shown in SEQ ID NO:7, HCDR2 with a sequence as shown in SEQ ID NO:8, HCDR3 with a sequence as shown in SEQ ID NO:9, and LCDR1 with a sequence as shown in SEQ ID NO:10, LCDR2 with a sequence as shown in SEQ ID NO:11, and LCDR3 with a sequence as shown in SEQ ID NO:12; (c) HCDR1 with a sequence as shown in SEQ ID NO:13, HCDR2 with a sequence as shown in SEQ ID NO:14, HCDR3 with a sequence as shown in SEQ ID NO:15, and LCDR1 with a sequence as shown in SEQ ID NO:16, and LCDR2 with a sequence as shown in SEQ ID NO:17. (d) HCDR1 with a sequence as shown in SEQ ID NO:19, HCDR2 with a sequence as shown in SEQ ID NO:20, HCDR3 with a sequence as shown in SEQ ID NO:21, and LCDR1 with a sequence as shown in SEQ ID NO:22, LCDR2 with a sequence as shown in SEQ ID NO:23, and LCDR3 with a sequence as shown in SEQ ID NO:24.
[0079] Preferably, the amino acid sequence of the heavy chain variable region of the Trop2 binding molecule of the present invention is shown in any one of SEQ ID NOs: 25, 27, 29 and 31; the amino acid sequence of the light chain variable region is shown in any one of SEQ ID NOs: 26, 28, 30 and 32.
[0080] The Trop2 binding molecules described herein can be monovalent or multivalent antibodies or multispecific antibodies comprising one, two or more anti-Trop2 antibodies or antigen-binding fragments described herein. The multispecificity can be directed against Trop2 and another antigen, or against two different epitopes of Trop2.
[0081] The present invention also includes the antibody derivatives and analogs. "Derivatives" and "analogs" refer to polypeptides that substantially maintain the same biological function or activity as the antibodies of the present invention. The derivatives or analogs of the present invention may be (i) polypeptides having a substitution group in one or more amino acid residues, or (ii) polypeptides formed by fusion of a mature polypeptide with another compound (such as a compound that prolongs the half-life of the polypeptide, such as polyethylene glycol), or (iii) polypeptides formed by fusion of an additional amino acid sequence to this polypeptide sequence (such as a leader sequence or secretory sequence or a sequence or proprotein sequence used to purify the polypeptide, or a fusion protein formed with a 6His tag). According to the teachings herein, these derivatives and analogs are within the scope known to those skilled in the art.
[0082] Under the premise of not substantially affecting the activity of the antibody, a person skilled in the art may change one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more) amino acids in the antibody sequence of the present invention to obtain variants of the antibody or its functional fragment sequence. These variants include (but are not limited to): one or more (usually 1-50, preferably 1-30, more preferably 1-20, and most preferably 1-10) amino acid deletions, insertions and / or substitutions, and addition of one or more (usually within 20, preferably within 10, and more preferably within 5) amino acids at the C-terminus and / or N-terminus. In the art, conservative substitutions with amino acids with similar or similar properties generally do not change the function of the protein. For example, amino acids with similar properties are substituted in the FR and / or Fc regions. Amino acid residues that can be conservatively substituted are well known in the art. Such substituted amino acid residues may or may not be encoded by the genetic code. For another example, adding one or more amino acids to the C-terminus and / or N-terminus will generally not change the function of the protein. They are all considered to be included in the scope of protection of the present invention.
[0083] Variant forms of the antibodies described herein include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, proteins encoded by DNA that can hybridize with the encoding DNA of the antibodies of the present invention under high or low stringency conditions, and polypeptides or proteins obtained using antiserum against the antibodies of the present invention. In some embodiments, the sequence of the variants of the present invention may have at least 95%, 96%, 97%, 98% or 99% identity with its source sequence. The sequence identity of the present invention can be measured using sequence analysis software. For example, the computer program BLAST, especially BLASTP or TBLASTN, using default parameters. The present invention also includes molecules having antibody heavy chain variable regions or light chain variable regions with CDRs, as long as their CDRs have more than 90% (preferably more than 95%, and most preferably more than 98%) homology with the CDRs identified herein.
[0084] The antibodies of the present invention can be prepared by conventional methods in the art, such as hybridoma technology. The single-chain antibodies of the present invention can be prepared by conventional methods in the art, such as phage display technology well known in the art. Alternatively, the antibodies or single-chain antibodies of the present invention can be expressed in other cell lines. Sequences encoding the antibodies of the present invention can be used to transform suitable mammalian host cells, and then the host cells are cultured and the antibodies are purified. The transformation can be carried out by any known method, for example, including packaging the polynucleotide in a virus (or a viral vector) and transducing the host cell with the virus (or vector). The transformation procedure used depends on the host to be transformed. Methods for introducing heterologous polynucleotides into mammalian cells are well known in the art, including dextran-mediated transfection, calcium phosphate precipitation, polybrene-mediated transfection, protoplast fusion, electroporation, encapsulation of polynucleotides in liposomes, and direct microinjection of DNA into the nucleus. Mammalian cell lines that can be used as hosts for expression are well known in the art, and include, but are not limited to, a variety of immortalized cell lines available from the American Type Culture Collection (ATCC), including, but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., HepG2), and the like.
[0085] CAR
[0086] The present invention also provides a chimeric antigen receptor (CAR) targeting Trop2. The CAR contains an optional signal peptide sequence, an antigen recognition region, i.e., an anti-Trop2 binding molecule described herein, a hinge region, a transmembrane region, and an intracellular region. The intracellular region comprises one or more intracellular costimulatory domains and / or one or more intracellular signaling domains. The "hinge region", "transmembrane region" and "intracellular region" herein can all be selected from the sequences of the hinge region, transmembrane region and intracellular region in known CAR-T technology.
[0087] The optional signal peptide on CAR can be selected as needed. In general, a signal peptide is a peptide sequence that targets a polypeptide to a desired site in a cell. The signal peptide targets the polypeptide to the secretory pathway of the cell and will allow the polypeptide to be integrated and anchored to the lipid bilayer; the signal peptide can also be a membrane localization signal peptide. Exemplary signal peptides such as CD8 signal peptides, CD28 signal peptides, CD4 signal peptides, or light chain signal peptides, the sequences of which are within the knowledge of those skilled in the art. The CD8 signal peptide suitable for the present invention may be various human CD8 signal peptide sequences commonly used in CAR in the art. In certain embodiments, the amino acid sequence of the CD8 signal peptide comprises the sequence shown in SEQ ID NO: 33, and the nucleotide sequence comprises the sequence shown in SEQ ID NO: 38.
[0088] The hinge region of the chimeric antigen receptor is located between the extracellular antigen binding region and the transmembrane region. The hinge region is an amino acid segment that usually exists between the two domains of the protein and can allow the flexibility of the protein and the relative movement of the two domains to each other. The hinge region can be a hinge region of a naturally occurring protein or a portion thereof. The hinge region of an antibody (such as an IgG, IgA, IgM, IgE or IgD antibody) can also be used for the chimeric antigen receptor described herein. Non-naturally occurring peptides can also be used as the hinge region of the chimeric antigen receptor described herein. Exemplarily, the hinge region of CAR is selected from a CD8α hinge region, an IgD hinge region, an IgG1 FcCH2CH3 hinge region or an IgG4 Fc CH2CH3 hinge region, and its sequence is within the knowledge of those skilled in the art. The CD8α hinge region suitable for the present invention can be various human CD8α hinge region sequences commonly used in CAR in the art. In certain embodiments, the human CD8α hinge region comprises the sequence shown in SEQ ID NO: 34, and the nucleotide sequence comprises the sequence shown in SEQ ID NO: 39.
[0089] The transmembrane region of the chimeric antigen receptor can form an alpha helix, a complex of more than one alpha helix, a beta barrel, or any other stable structure capable of spanning a cell phospholipid bilayer. The transmembrane region can be of natural or synthetic origin. The transmembrane region can be selected from the transmembrane region of the following proteins: CD3ε, CD4, CD5, CD8α, CD9, CD16, CD22, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD134, CD137, CD154, α, β or ζ chain of T cell receptor. The human CD8α transmembrane region suitable for the present invention can be various human CD8α transmembrane region sequences commonly used in CAR in the art. In certain embodiments, the amino acid sequence of the human CD8α transmembrane region comprises the sequence shown in SEQ ID NO:35, and the nucleotide sequence comprises the sequence shown in SEQ ID NO:40.
[0090] The intracellular signaling region (or intracellular signaling region) is responsible for the activation of at least one normal effector function of the immune effector cell expressing the chimeric antigen receptor. For example, the effector function of the T cell can be cell lysis activity or auxiliary activity, including the secretion of cytokines. Although the entire intracellular signaling region can usually be used, in many cases, it is not necessary to use the entire chain. In terms of using a truncated portion of the intracellular signaling region, as long as it transduces the effector function signal, this truncated portion can be used instead of the complete chain. Therefore, the intracellular signaling region includes any truncated form of the intracellular signaling region sufficient to transduce the effector function signal. The intracellular signaling domain of the CAR can be selected as needed, including but not limited to an intracellular signaling domain derived from at least one of CD3ζ, FcRγ (FCER1G), FcRβ (FcεRib), CD3γ, CD3δ, CD3ε, CD5, CD22, CD79a, CD79b and CD66d. Preferably, the intracellular signaling region is derived from the human CD3ζ intracellular signaling region. Furthermore, the human CD3ζ intracellular signal region has the amino acid sequence shown in SEQ ID NO:37, and the nucleotide sequence includes the sequence shown in SEQ ID NO:42.
[0091] In addition to the stimulation of antigen-specific signals, many immune effector cells also require co-stimulation to promote cell proliferation, differentiation and survival, as well as to activate the effector functions of cells. A "co-stimulatory domain" can be the cytoplasmic portion of a co-stimulatory molecule. The term "co-stimulatory molecule" refers to an associated binding partner on an immune cell (such as a T cell) that specifically binds to a co-stimulatory ligand, thereby mediating a co-stimulatory response by the immune cell, such as but not limited to proliferation and survival. Suitable intracellular costimulatory domains can be selected as needed, including intracellular domains with costimulatory signal molecules, such as from 4-1BB, CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54, CD83, OX40, CD137, CD134, CD150, CD152, CD223, CD270, PD-L2, PD-L1, CD278, DAP10, LAT, NKD2C, SLP76, TRIM, FcεRIγ, MyD88, and at least one of the intracellular domains of 41BBL. In certain embodiments, the amino acid sequence of the 4-1BB costimulatory domain comprises the sequence shown in SEQ ID NO:36, and the nucleotide sequence comprises the sequence shown in SEQ ID NO:41.
[0092] The above-mentioned parts forming the chimeric antigen receptor of the present invention, such as CD8 signal peptide, anti-Trop2 single-chain antibody, CD8α hinge region, CD8α transmembrane region, CD3ζ intracellular signal domain, 4-1BB costimulatory domain, etc., can be directly connected to each other, or can be connected through a linker sequence. The linker sequence can be a linker sequence suitable for antibodies known in the art, such as a linker sequence containing G and S. Generally, the linker contains one or more motifs repeated before and after. For example, the motif can be GGGS, GGGGS, SSSSG, GSGSA and GGSGG. Preferably, the motif is adjacent in the linker sequence, and no amino acid residues are inserted between the repeats. The linker sequence can be composed of 1, 2, 3, 4 or 5 repeating motifs. The length of the linker can be 3 to 25 amino acid residues, such as 3 to 15, 5 to 15, 10 to 20 amino acid residues. In certain embodiments, the linker sequence is a polyglycine linker sequence. The number of glycine residues in the linker sequence is not particularly limited, and is generally 2 to 20, such as 2 to 15, 2 to 10, or 2 to 8. In addition to glycine and serine, the linker may also contain other known amino acid residues, such as alanine (A), leucine (L), threonine (T), glutamic acid (E), phenylalanine (F), arginine (R), glutamine (Q), etc. In certain embodiments, the linker sequence is (GGGGS)n, where n is an integer of 1 to 5.
[0093] In an exemplary embodiment, CAR contains, from N-terminus to C-terminus, a CD8 signal peptide, an anti-Trop2 antibody or an antigen-binding fragment thereof described herein, a CD8α hinge region, a CD8α transmembrane region, a 4-1BB co-stimulatory domain, and a CD3ζ intracellular signaling domain.
[0094] It should be understood that in gene cloning operations, it is often necessary to design suitable restriction sites, which will inevitably introduce one or more irrelevant residues at the end of the expressed amino acid sequence, which does not affect the activity of the target sequence. In order to construct fusion proteins, promote the expression of recombinant proteins, obtain recombinant proteins that are automatically secreted outside the host cell, or facilitate the purification of recombinant proteins, it is often necessary to add some amino acids to the N-terminus, C-terminus or other suitable regions within the protein of the recombinant protein, for example, including but not limited to suitable linker peptides, signal peptides, leader peptides, terminal extensions, etc. Therefore, the amino or carboxyl terminus of the CAR of the present invention may also contain one or more polypeptide fragments as protein tags. Any suitable tag can be used herein. For example, the tag may be FLAG, HA, HA1, c-Myc, Poly-His, Poly-Arg, Strep-TagII, AU1, EE, T7, 4A6, ε, B, gE and Ty1. These tags can be used to purify proteins.
[0095] The antigen recognition region in the CAR of the present invention may be a variant of the aforementioned anti-Trop2 antibody or its functional fragment sequence. In addition, other parts of the CAR may also undergo sequence changes, and the resulting mutant has at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97% sequence identity with the CAR and retains the biological activity of the CAR (such as activated T cells). The sequence identity between the two aligned sequences can be calculated using, for example, NCBI's BLASTp.
[0096] Mutants also include: amino acid sequences having one or more mutations (insertions, deletions or substitutions) in the amino acid sequence of the CAR described in any embodiment, while still retaining the biological activity of the CAR. The several mutations generally refer to within 1-10, such as 1-8, 1-5 or 1-3. The substitution is preferably a conservative substitution. For example, in the art, when conservative substitutions are made with amino acids with similar or similar properties, the function of the protein or polypeptide is generally not changed. "Amino acids with similar or similar properties" include, for example, families of amino acid residues with similar side chains, including amino acids with basic side chains (e.g., lysine, arginine, histidine), amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), amino acids with uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), amino acids with non-polar side chains (e.g., alanine, valine, leucine, isoleucine proline, phenylalanine, methionine, tryptophan), amino acids with β-branched side chains (e.g., threonine, valine, isoleucine) and amino acids with aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Therefore, replacing one or several sites in the polypeptide of the present invention with another amino acid residue from the same side chain class will not substantially affect its activity.
[0097] Nucleic Acids
[0098] The present invention also provides polynucleotides encoding the above-mentioned antibodies or CARs. The polynucleotides of the present invention may be in the form of DNA or RNA. DNA forms include cDNA, genomic DNA or artificially synthesized DNA. DNA may be single-stranded or double-stranded. DNA may be a coding strand or a non-coding strand. The present invention also includes degenerate variants of polynucleotide sequences encoding fusion proteins, i.e., nucleotide sequences encoding the same amino acid sequence but with different nucleotide sequences.
[0099] Therefore, the present invention also relates to polynucleotides that hybridize to the above-mentioned polynucleotide sequence and have at least 50%, preferably at least 70%, and more preferably at least 80% identity between the two sequences. The present invention particularly relates to polynucleotides that can hybridize to the polynucleotides of the present invention under stringent conditions. In the present invention, "stringent conditions" refer to: (1) hybridization and elution at relatively low ionic strength and relatively high temperature, such as 0.2×SSC, 0.1% SDS, 60°C; or (2) addition of denaturing agents during hybridization, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% Ficoll, 42°C, etc.; or (3) hybridization occurs only when the identity between the two sequences is at least 90%, and more preferably at least 95%. In addition, the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide.
[0100] The full-length nucleotide sequence of the antibody of the present invention or its fragment can usually be obtained by PCR amplification, recombination or artificial synthesis. A feasible method is to synthesize the relevant sequence by artificial synthesis, especially when the fragment length is short. Usually, a fragment with a very long sequence can be obtained by first synthesizing multiple small fragments and then connecting them. In addition, the coding sequence of the heavy chain or light chain and the expression tag (such as 6His) can be fused together to form a fusion protein. The sequence of CAR can also be obtained as above. Alternatively, the sequences of the various parts of CAR (signal peptide, antigen recognition region, hinge region, transmembrane region or intracellular region) can be obtained as above and then connected to obtain the full length of CAR.
[0101] Once the relevant sequence is obtained, the relevant sequence can be obtained in large quantities by recombinant methods. This is usually cloned into a vector, then transferred into a cell, and then the relevant sequence is isolated from the host cell after proliferation by conventional methods. The biological molecules (nucleic acids, proteins, etc.) involved in the present invention include biological molecules in a separated form. At present, the DNA sequence encoding the protein of the present invention (or its fragment, or its derivative) can be obtained completely by chemical synthesis. The DNA sequence can then be introduced into various existing DNA molecules (or such as vectors) and cells known in the art. In addition, mutations can also be introduced into the protein sequence of the present invention by chemical synthesis. The various parts of CAR can be cloned into the vector sequentially or can be integrated into the full-length CAR and then cloned.
[0102] The present invention also relates to a nucleic acid construct comprising a polynucleotide sequence as described herein, and one or more regulatory sequences operably linked to these sequences. The polynucleotide sequence of the present invention can be manipulated in a variety of ways to ensure the expression of the antibody or CAR. Before inserting the nucleic acid construct into the vector, the nucleic acid construct can be manipulated according to the different or required expression vectors. The technology of using recombinant DNA methods to change polynucleotide sequences is known in the art.
[0103] The regulatory sequence can be a suitable promoter sequence. The promoter sequence is usually operably connected to the coding sequence of the protein to be expressed. The promoter can be any nucleotide sequence showing transcriptional activity in the selected host cell, including mutations, truncations and hybrid promoters, and can be obtained from the gene encoding the extracellular or intracellular polypeptides homologous or heterologous to the host cell. An example of a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. The promoter sequence is a strong constitutive promoter sequence that can drive any polynucleotide sequence high-level expression that is operably connected thereto. Another example of a suitable promoter is elongation growth factor-1 alpha (EF-1 alpha). However, other constitutive promoter sequences may also be used, including but not limited to simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, avian leukemia virus promoter, Epstein-Barr virus immediate early promoter, Rous sarcoma virus promoter, and human gene promoters, such as but not limited to actin promoter, myosin promoter, heme promoter and creatine kinase promoter. Further, inducible promoters may also be considered. The use of inducible promoters provides a molecular switch that can turn on the expression of a polynucleotide sequence operably connected to an inducible promoter when the expression is limited, and turn off the expression when the expression is not expected. Examples of inducible promoters include but are not limited to metallothionein promoters, glucocorticoid promoters, progesterone promoters and tetracycline promoters.
[0104] The regulatory sequence may also be a suitable transcription terminator sequence, a sequence recognized by the host cell to terminate transcription. The terminator sequence is operably linked to the 3' end of the nucleotide sequence encoding the polypeptide. Any terminator that is functional in the selected host cell can be used in the present invention. The regulatory sequence may also be a suitable leader sequence, a non-translated region of an mRNA that is important for host cell translation. The leader sequence is operably linked to the 5' end of the nucleotide sequence encoding the polypeptide. Any terminator that is functional in the selected host cell can be used in the present invention.
[0105] In certain embodiments, the nucleic acid construct is a vector, such as a cloning vector, an expression vector, and an integration vector. Expression of the polynucleotide sequence of the present invention is usually achieved by operably connecting the polynucleotide sequence of the present invention to an expression vector. Typical cloning vectors contain transcription and translation terminators, initiation sequences, and promoters that can be used to regulate the expression of the desired nucleic acid sequence. Integration vectors contain components that integrate the target sequence into the cell genome. These vectors can be used to transform appropriate host cells to enable them to express proteins. Vectors usually contain sequences for plasmid maintenance and for cloning and expressing exogenous nucleotide sequences. The sequences (collectively referred to as "flanking sequences" in certain embodiments) usually include one or more of the following nucleotide sequences: a promoter, one or more enhancer sequences, a replication origin, a transcription termination sequence, a complete intron sequence containing donor and acceptor splice sites, a sequence encoding a leader sequence for polypeptide secretion, a ribosome binding site, a polyadenylation sequence, a multi-linker region for inserting a nucleic acid encoding an antibody to be expressed, and a selectable marker element.
[0106] In addition, the type of vector is not limited, for example, plasmid, phagemid, phage derivative, animal virus and cosmid, can be changed according to the host cell to be introduced. Viral vector technology is well known in the art and is described in, for example, Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York) and other virology and molecular biology manuals. Viruses that can be used as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpes viruses and slow viruses.
[0107] To assess the expression of a CAR polypeptide or portion thereof, the vector introduced into the cell may also contain either or both a selectable marker gene or a reporter gene to facilitate identification and selection of expressing cells from the population of cells sought to be transfected or infected by the viral vector.
[0108] cell
[0109] The host cells suitable for introducing the nucleic acid constructs described herein can be prokaryotic cells, such as bacterial cells; or lower eukaryotic cells, such as yeast cells; or higher eukaryotic cells, such as mammalian cells, especially immune cells, preferably immune effector cells. Representative examples include: Escherichia coli, Streptomyces; bacterial cells of Salmonella typhimurium; fungal cells such as yeast; insect cells of Drosophila S2 or Sf9; animal cells of CHO, COS7, 293 cells, etc.
[0110] "Immune effector cells" are immune cells that can perform immune effector functions. In some embodiments, immune effector cells express at least FcγRIII and perform ADCC effector functions. Examples of immune effector cells that mediate ADCC include peripheral blood mononuclear cells (PBMCs), natural killer (NK) cells, monocytes, cytotoxic T cells, neutrophils, and eosinophils. Preferably, immune effector cells are selected from at least one of immune cells, T lymphocytes, NK cells, peripheral blood mononuclear cells (PBMCs), and hematopoietic stem cells cultured and differentiated from pluripotent stem cells or embryonic stem cells. More preferably, the immune effector cells are T lymphocytes (same as T cells). In some embodiments, T cells can be CD4+ / CD8-, CD4- / CD8+, CD4+ / CD8+, CD4- / CD8-, or a combination thereof. In some embodiments, T cells produce IL-2, IFN, and / or TNF when expressing chimeric antigen receptors and binding to target cells. In some embodiments, CD8+ T cells lyse antigen-specific target cells when they express a chimeric antigen receptor and bind to the target cell.
[0111] T cells suitable for the present invention can be various types of T cells from various sources. For example, T cells can be derived from PBMCs of patients with malignant solid tumors (e.g., pancreatic cancer). In certain embodiments, after obtaining T cells, they can be first stimulated and activated with an appropriate amount (e.g., 30 to 80 ng / ml, such as 50 ng / ml) of CD3 antibodies, and then cultured in an IL2 medium containing an appropriate amount (e.g., 30 to 80 IU / ml, such as 50 IU / ml) for standby use.
[0112] Methods for introducing nucleic acids or vectors into mammalian cells are known in the art, and the vectors can be transferred into cells by physical, chemical or biological methods. When the host is a prokaryotic organism such as Escherichia coli, competent cells that can absorb DNA can be harvested after the exponential growth phase and treated with the CaCl2 method, and the steps used are well known in the art. When the host is a eukaryotic organism, the following DNA transfection methods can be selected: calcium phosphate coprecipitation, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc. In some embodiments, the transduced or transfected immune effector cells are propagated in vitro after the introduction of nucleic acids or vectors.
[0113] The obtained transformant can be cultured by conventional methods to express the antibody or CAR encoded by the gene of the present invention. Depending on the host cell used, the culture medium used in the culture can be selected from various conventional culture media. Culture is carried out under conditions suitable for the growth of host cells. When the host cells grow to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
[0114] The polypeptide in the above method can be expressed in the cell, on the cell membrane, or secreted outside the cell. If necessary, the recombinant protein can be separated and purified by various separation methods using its physical, chemical and other properties. These methods are well known to those skilled in the art. Examples of these methods include but are not limited to: conventional renaturation treatment, treatment with protein precipitants (salting out method), centrifugation, osmotic sterilization, ultra-treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography techniques and combinations of these methods.
[0115] Uses and methods
[0116] By constructing a single-chain antibody library, the inventors screened single-chain antibodies that can bind to Trop2. Using these single-chain antibodies, the inventors constructed CAR and CAR-T cells. Cell-level experiments have shown that the CAR-T has strong immune function, better CD107a expression, IFN-γ and IL-2 secretion, and specific killing function of target cells, and significant in vivo efficacy.
[0117] All aspects of the antibodies, CARs, coding sequences, nucleic acid constructs, and cells described herein can be used to prepare drugs for preventing or treating the various conditions and diseases described herein, which are diseases or conditions associated with Trop2 expression, referring to diseases caused directly or indirectly by abnormal Trop2 expression, generally referring to diseases caused by overexpression of Trop2, such as cancer, including but not limited to: breast cancer, gastric cancer, colorectal cancer, pancreatic cancer, prostate cancer, cervical cancer, head and neck cancer, lung cancer and ovarian cancer.
[0118] The present invention also includes a class of cell therapies, including expressing the CAR described herein in immune cells (e.g., T cells), and administering a therapeutically effective amount of cells to a recipient in need thereof, the cells being capable of killing the recipient's tumor cells. Compared to antibody therapy, CAR-T cells are able to replicate in vivo, producing long-term persistence that can lead to sustained tumor control. The anti-tumor immune response caused by CAR-T cells can be an active or passive immune response. In addition, the CAR-mediated immune response can be part of an adoptive immunotherapy step, in which the CAR-T cells induce an immune response specific to the antigen binding portion in the CAR.
[0119] The antibodies, nucleic acids or CAR-modified cells of the present invention may be administered alone or as a pharmaceutical composition in combination with a diluent and / or with other components such as related cytokines or cell populations. In this regard, the pharmaceutical composition can be prepared in the form of a lyophilized preparation or an aqueous solution by mixing an active agent having the desired purity with an optional pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier is non-toxic to the recipient at the dose and concentration used, and may include at least one of a buffer (e.g., neutral buffered saline, sulfate buffered saline), an antioxidant, a preservative, an isotonic agent, a stabilizer, a chelating agent (e.g., EDTA or glutathione), an adjuvant (e.g., aluminum hydroxide), and a surfactant. In addition, in order for the pharmaceutical composition to be useful for in vivo administration, they must be sterile. The pharmaceutical composition may be sterilized by filtration through a sterile filtration membrane.
[0120] In some embodiments, the pharmaceutical composition may contain: at least one additive selected from the group consisting of a cytotoxic agent, a chemotherapeutic agent, a cytokine, an immunosuppressant, a growth inhibitor, and an active agent required for the specific indication to be treated. The specific amount of the additive added may be adjusted according to actual needs. The pharmaceutical composition of the present invention may be administered in an "immunologically effective amount", "anti-tumor effective amount", "tumor-suppressive effective amount" or "therapeutic amount". "Treatment" refers to the subject adopting the treatment regimen described herein to achieve at least one positive therapeutic effect (e.g., a decrease in the number of cancer cells, a decrease in tumor volume, a decrease in the rate of cancer cell infiltration to peripheral organs, or a decrease in the rate of tumor metastasis or tumor growth). When an "immunologically effective amount", "anti-tumor effective amount", "tumor-suppressive effective amount" or "therapeutic amount" is indicated, the exact amount of the composition of the present invention to be administered may be determined by a physician, taking into account individual differences in the patient's (subject's) age, weight, tumor size, degree of infection or metastasis, and condition. Typically, the pharmaceutical composition comprising the T cells described herein may be administered in an amount of 10 4 Up to 10 9 The dosage is preferably 10 cells / kg body weight. 5 Up to 10 6 The T cell composition can also be administered multiple times at these doses. The cells can be administered using well-known infusion techniques in immunotherapy (see, e.g., Rosenberg et al., New Eng. J. of Med. 319:1676, 1988). The optimal dose and treatment regimen for a particular patient can be easily determined by a medical technician by monitoring the patient's disease signs and adjusting the treatment accordingly.
[0121] Administration of the composition can be carried out in any convenient manner, including by spraying, injection, swallowing, infusion, implantation or transplantation. The composition described herein can be administered to the patient subcutaneously, intradermally, intratumorally, intranodally, intraspinal, intramuscularly, by intravenous injection or intraperitoneally. In one embodiment, the T cell composition of the present invention is administered to the patient by intradermal or subcutaneous injection. In another embodiment, the T cell composition of the present invention is preferably administered by intravenous injection. The composition of the T cell can be directly injected into a tumor, lymph node or infection site.
[0122] In some embodiments of the present invention, the CAR-T cells or compositions thereof of the present invention may be combined with other therapies known in the art. The therapies include, but are not limited to, chemotherapy, radiotherapy, and immunosuppressants. For example, the treatment may be combined with radiotherapy or chemotherapy agents known in the art for treating mesothelin-mediated diseases.
[0123] Herein, "anti-tumor effect" refers to a biological effect which can be represented by a reduction in tumor volume, a reduction in the number of tumor cells, a reduction in the number of metastases, an increase in life expectancy, or an improvement in various physiological symptoms associated with cancer.
[0124] "Patient", "subject", "individual" and the like are used interchangeably herein and refer to a living organism, such as a mammal, that can elicit an immune response. Examples include, but are not limited to, humans, dogs, cats, mice, rats, and transgenic species thereof.
[0125] Diagnostics, Tests and Kits
[0126] The binding molecules of the present invention can be used in assays, such as binding assays, to detect and / or quantify Trop2 expressed in tissues or cells due to their high affinity for Trop2. Binding molecules such as single-chain antibodies can be used in studies to further study the role of Trop2 in disease. The method for detecting Trop2 is generally as follows: obtaining a cell and / or tissue sample; detecting the level of Trop2 in the sample.
[0127] The Trop2 binding molecules of the present invention can be used for diagnostic purposes to detect, diagnose or monitor diseases and / or conditions associated with Trop2. The present invention provides for detecting the presence of Trop2 in a sample using classical immunohistological methods known to those skilled in the art. Detection of Trop2 can be performed in vivo or in vitro. Examples of methods suitable for detecting the presence of Trop2 include ELISA, FACS, RIA, etc.
[0128] For diagnostic applications, binding molecules such as single-chain antibodies are typically labeled with a detectable labeling group. Suitable labeling groups include, but are not limited to, the following: radioisotopes or radionuclides (e.g., 3H, 14C, 15N, 35S, 90Y, 99Tc, 111In, 125I, 131I), fluorescent groups (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic groups (e.g., horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase), chemiluminescent groups, biotinyl groups, or predetermined polypeptide epitopes recognized by secondary reporters (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags), MRI (magnetic resonance imaging) or CT (computer tomography) contrast agents. Various methods for labeling proteins are known in the art and can be used to perform the present invention.
[0129] Another aspect of the invention provides a method for detecting the presence of a test molecule that competes with the antibody of the invention for binding to Trop2. An example of such an assay would involve detecting the amount of free antibody in a solution containing a certain amount of Trop2 in the presence or absence of the test molecule. An increase in the amount of free antibody (i.e., antibody that is not bound to Trop2) would indicate that the test molecule can compete with the antibody for binding to Trop2. In one embodiment, the antibody is labeled with a labeling group. Alternatively, the test molecule is labeled and the amount of free test molecule is monitored in the presence or absence of the antibody.
[0130] The present invention also provides a detection kit for detecting Trop2 levels, which includes an antibody that recognizes Trop2 protein, a lysis medium for dissolving the sample, and universal reagents and buffers required for detection, such as various buffers, detection markers, detection substrates, etc. The detection kit can be an in vitro diagnostic device.
[0131] The present invention will be described below in the form of specific examples. It should be understood that these examples are merely illustrative and are not intended to limit the scope of the present invention. The methods and materials used in the examples are, unless otherwise stated, materials and methods conventional in the art. Example
[0132] Example 1: Construction of recombinant human Trop2 protein expression vector and eukaryotic expression
[0133] 1. Synthesis of gene sequences and construction of protein expression vectors
[0134] The human Trop2 protein sequence was downloaded from Uniport (https: / / www.uniprot.org / uniprot), and after optimization by the codon online optimization tool (http: / / www.jcat.de / #opennewwindow), it was handed over to Bioengineering to synthesize the Trop2 extracellular segment gene sequence. At the same time, the nucleic acid sequences of avi-tag and 6×his-tag were added to the 3' end of the gene sequence. The fusion gene sequence encodes the amino acid sequence shown in SEQ ID NO:51, and the sequence of the fusion gene is shown in SEQ ID NO:52. Through molecular cloning, the spliced product was cloned into pTT5 using the TaKaRa seamless cloning kit to obtain an expression vector.
[0135] 2. Expression and purification of recombinant human Trop2 protein
[0136] After 5 days of transfection of 293T cells (ATCC) with the obtained expression vector, the culture supernatant was collected and the recombinant human Trop2 protein was purified using AKTA Explorer 100 (GE). After SDS-PAGE electrophoresis and Coomassie Brilliant Blue staining, the Trop2 protein showed that its size was about 36 kilodaltons. Figure 1 shown.
[0137] Example 2: Preparation of anti-human Trop2 antibody
[0138] 1. Construction of scFv phage display library
[0139] A two-step method is used to construct a human natural antibody phage display library, that is, the human natural antibody light chain variable region gene and heavy chain variable region gene are connected to the phage display vector in two steps.
[0140] 1) κ chain, λ chain variable region gene amplification
[0141] Human immunoglobulin κ chain variable region forward primer (3z3-1-F) and reverse primer (Huvksc-R) were used as templates to amplify human immunoglobulin κ chain variable region gene by PCR, and human immunoglobulin λ chain variable region forward primer (3z3-1-F) and reverse primer (HuvLR-1) were used as templates to amplify human immunoglobulin λ chain variable region gene by PCR. The PCR reaction conditions were as follows: pre-denaturation at 98℃ for 45 seconds, followed by temperature cycling, denaturation at 98℃ for 15 seconds, annealing at 60℃ for 20 seconds, extension at 72℃ for 23 seconds, 30 cycles, and final extension at 72℃ for 5 minutes. After PCR products were subjected to 1.5% agarose gel electrophoresis, the κ chain variable region gene fragment and the λ chain variable region gene fragment of about 330 bp were recovered using a gel recovery kit (Promega).
[0142] 2) Construction of κ chain and λ chain libraries
[0143] The κ chain gene, λ chain gene and phagemid pcomb3sc were double digested with NheI-HF and SalI-HF DNA endonucleases (NEB), and the κ chain gene and λ chain gene after digestion were directly recovered using a gel recovery kit. After 1% agarose gel electrophoresis, the pcomb3sc vector after digestion was recovered with a gel recovery kit (Promega) for a 4000bp vector fragment. The κ chain gene and λ chain gene were ligated to the pcomb3sc vector using a T4 DNA ligase kit (Invitrogen), pcomb3sc 1000ng, κ and λ were used 200ng respectively, and multiple reaction tubes were prepared, 50μl / tube, and the connection was carried out at 16℃ overnight. A small amount of the connection product was taken for agarose gel electrophoresis to detect the connection efficiency. The connection product was desalted using a MECK MILLIPOREF microporous filter membrane. The desalted ligation product was electroporated into homemade TG1 electrocompetent cells to obtain the κ chain library and the λ chain library. The electroporated κ chain library and the λ chain library were amplified overnight, and the κ chain library plasmid and the λ chain library plasmid were extracted using a plasmid extraction kit (NucleoBond Xtra Maxi EF) the next day.
[0144] 3) Heavy chain variable region VH gene amplification
[0145] Human immunoglobulin heavy chain variable region forward primer (VH-MIX 1 / 7) and reverse primer (VH-MIX R), human immunoglobulin heavy chain variable region forward primer (VH-MIX3) and reverse primer (VH-MIX R), human immunoglobulin heavy chain variable region forward primer (VH-MIX4) and reverse primer (VH-MIX R) were used to amplify human immunoglobulin VH variable region genes by PCR using human PBMC cDNA as template. The PCR reaction conditions were as follows: pre-denaturation at 98°C for 45 seconds followed by temperature cycling, denaturation at 98°C for 15 seconds, annealing at 60°C for 20 seconds, extension at 72°C for 23 seconds, 30 cycles, and final extension at 72°C for 5 minutes. After 1% agarose gel electrophoresis, the PCR product was recovered using a gel recovery kit (Promega) to recover a VH gene fragment of about 330 bp.
[0146] 4) scFv library construction
[0147] The recovered VH fragments were mixed in equal proportions and digested with the above-mentioned κ chain library plasmid and λ chain library plasmid using SfiI DNA endonuclease. The digestion was carried out at 50℃ for 16h. The VH gene after digestion was directly recovered by column using gel recovery kit. After 1% agarose gel electrophoresis of the κ chain library and λ chain library after digestion, the vector fragment of about 4000bp was recovered using gel recovery kit (Promega). The VH gene was connected to the κ chain and λ chain vector libraries using T4 DNA ligase kit (Invitrogen), i.e., pcomb3sc-lambda / kappa (SfiI) 1000ng, VH amplify mix (sfiI) 200ng, and multiple reaction tubes were prepared, 50μl / tube, and the connection was carried out at 16℃ overnight. A small amount of the connection product was taken for agarose gel electrophoresis to detect the connection efficiency. The connection product was desalted using MECK MILLIPOREF microporous filter membrane.
[0148] Add the above ligation product to the homemade TG1 electroporation competent medium, and then use an electroporator to perform electroporation. Take out 50 μL of bacterial solution and dilute it with PBS for 10 steps. 2 -10 5 Times. Take 10μL of each gradient dilution and flow line on Amp / 2YT plate, incubate at 37℃ overnight, count and calculate the size of phage antibody library. The remaining electroporated bacteria are supplemented with 2YT to 500ml, and 100mg / ml ampicillin is added to the mother solution at 1:1000, and cultured at 30℃ 220rpm overnight. Finally, a scFv immune library of more than 3E10 is obtained. The electroporated antibody library is amplified overnight, and the library cells are collected by centrifugation, and a final concentration of 20% glycerol is added to store at -80 degrees.
[0149] 5) Phage display library
[0150] Take some frozen human natural antibody scFv library strains and inoculate them into 2YT medium with an inoculation density of 0.1OD. The bacterial solution is placed at 37℃ and 220rpm for culture. After about 1.5 hours, the bacterial solution density reaches 0.6OD. At this time, add 20 times the number of bacteria M13KO7 phages and let it stand for 30 minutes for infection, and then culture it at 30℃ and 220rpm overnight. The next day, centrifuge the bacterial solution at 10000g, collect the culture supernatant, add 1 / 4 volume of 5×PEG / NaCl solution (20%PEG8000, 2.5M NaCl) to the culture supernatant, mix well and ice bath for 1 hour. After the ice bath, centrifuge at 8000g for 10 minutes to collect the precipitate, dissolve the precipitate with 10% Glycerol / PBST to obtain the human natural antibody phage display library. Measure OD268, and dispense it into 1.5mL centrifuge tubes, 6OD / tube, and store at -80℃.
[0151] 2. Selection of Trop2 scFv Antibodies
[0152] 1) Recombinant human Trop2 protein coupled to streptavidin magnetic beads
[0153] The avi-tag of the recombinant human Trop2 protein was modified with biotin using a biotinylation kit (Genecopoeia) according to the kit instructions to obtain biotinylated Trop2 protein. 10 μg of the above biotinylated recombinant protein was added to 100 μL streptavidin magnetic beads (DynaBeads 280) washed 3 times with PBS, placed on a rotating shaker at 20 rpm, coupled at room temperature for 1 hour, and then washed 3 times with PBS.
[0154] 2) Blocking phage library and negative magnetic beads
[0155] Take one Kappa-scFv library and one Lambda-scFv library, melt them at room temperature, add 200 μL 5% BSA / PBST to each, place them on a rotating shaker at 20 rpm, and rotate and block at room temperature for 1 hour. These phages are Input 1. At the same time, take 100 μL of DynaBeads 280 without protein coupling, wash them 3 times with PBS, add 1 mL 1% BSA / PBS, and rotate and incubate them for 1 hour under the above conditions.
[0156] 3) Blocking positive magnetic beads
[0157] Add 1 mL of 1% BSA / PBS to the Trop2-coupled magnetic beads and rotate at 20 rpm for 1 hour at room temperature for blocking.
[0158] 4) Negative panning
[0159] To remove antibodies that interact with magnetic beads, negative panning is necessary. Mix the BSA-blocked phage library (Input 1) and magnetic beads that are not coupled to antigens, and incubate for 1 hour under the above conditions. After the incubation, place the phage-magnetic bead mixture on a magnetic stand, and after the magnetic beads are attached to the wall, transfer the supernatant to a new EP tube.
[0160] 5) Positive panning
[0161] Add the blocked magnetic beads coupled with Trop2 protein to the phage supernatant after negative panning for positive panning, and rotate at 20rpm at room temperature for 1 hour. After incubation, wash the magnetic beads with 1mL PBST (PBS with 0.1% Tween-20), and repeat the wash 10 times. After washing, add 1mL 100mM glycine (pH2.0), place on a rotating shaker with a speed of 20rpm, and rotate for 10 minutes. After elution, place the EP tube on the magnetic rack, and transfer the eluate to a new EP tube after the magnetic beads are attached to the wall. Add 0.2mL 1M Tris-HCl solution (pH 8.0) to the eluate for neutralization. The neutralized eluate was added to 30 mL of TG1 bacterial solution with an OD600 of about 0.6 and allowed to infect for 30 minutes. Then, 20 times the number of M13KO7 phages was added and allowed to infect for 30 minutes. Finally, 100 mL of 2YT medium and ampicillin and kanamycin with a final concentration of 100 μg / mL were added and cultured overnight at 30°C and 220 rpm. The next day, phages were harvested according to the above method for harvesting phage libraries. The phages obtained at this time were Input2.
[0162] 6) Repeat positive panning
[0163] The above panning method was repeated twice, that is, Input2 was subjected to the next round of negative and positive panning to obtain Input3. The difference was that after the eluate obtained by the panning of Input3 was infecting TG1, M13KO7 was not added, but 10μl of the bacterial solution was taken and graded diluted with PBS, and 10 3 , 10 4 , 10 5 100 μl of each bacterial solution from the three dilution gradients was spread on 2YT / Amp plates and cultured at 30°C overnight. The remaining bacterial solution was cultured at 30°C and 220 rpm overnight.
[0164] 7) ELISA screening for positive antibodies
[0165] Use a toothpick to randomly pick the TG1 monoclone from the above plate and put it into 800μL deep-well plate containing 10× auto-inducing 2YT / Amp. The deep-well plate is covered with a breathable membrane and cultured at 37℃ and 220rpm for 3 hours, and then cultured at 30℃ and 220rpm overnight. The ELISA plate is coated with recombinant human Trop2 protein, 100ng per well. The next day, 50μl of bacteria were first taken from the deep-well plate, and the rest was centrifuged at 4000rpm for 10 minutes. The culture medium in the well was removed to retain the bacterial sediment. 100μl TES solution (20% sucrose, 0.1mM EDTA, 50mMTris-HCl, pH 8.0) was added to each well. After shaking to resuspend the bacteria, ice bath for 30 minutes, 200μL ultrapure water was added and shaken for 30 minutes. After shaking, centrifuged at 4000rpm for 10 minutes. At this time, the supernatant solution in the deep-well plate is the periplasmic cavity extract containing antibodies. Wash the ELISA plate three times with a plate washer, then add 200μL 1% BSA / PBS and block at 37℃ for 1 hour. Remove the blocking solution from the ELISA plate, add 100μL of the above periplasmic extract, incubate at 37℃ for 1 hour (also as a control for tocilizumab), wash 3 times with a plate washer, add HRP Anti-HA tag antibody (ab1190) (1% BSA / PBS), incubate at 37℃ for 1 hour, wash 3 times with a plate washer, add 100μL TMB colorimetric solution, color at 37℃ for 10 minutes, and add 100μL Stopsolution. Read the OD450 value with an ELISA reader, and perform Sanger sequencing on clones with a reading value 3 times higher than the background value to obtain the gene sequence of the antibody.
[0166] 8) Verify positive clones
[0167] According to the sequencing results, clones with large differences in antibody CDR3 amino acid sequences were selected and re-inoculated and induced overnight, and the ELISA method was used to verify again whether the selected clones could bind to Trop2. Finally, four good antibody sequences, L2A8, L3G1, K2G2, and L3F4, were obtained.
[0168] The amino acid sequence of the heavy chain variable region of L2A8 is shown in SEQ ID NO: 25, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 26. The sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are GYSFTNYD (SEQ ID NO: 1), INPNSGNT (SEQ ID NO: 2), VRGRSYYYDKRGHYLNWYFDT (SEQ ID NO: 3), SSDVGGYNY (SEQ ID NO: 4), DV (SEQ ID NO: 5), and GSYTSNNIPWV (SEQ ID NO: 6), respectively.
[0169] The amino acid sequence of the heavy chain variable region of L3G1 is shown in SEQ ID NO: 27, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 28. The sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are GYSFTSYW (SEQ ID NO: 7), IYPGDSDT (SEQ ID NO: 8), ARLGGSYYYYGMDV (SEQ ID NO: 9), SSDFFNYHF (SEQ ID NO: 10), DV (SEQ ID NO: 11), and SSYTNSGTWV (SEQ ID NO: 12), respectively.
[0170] The amino acid sequence of the heavy chain variable region of K2G2 is shown in SEQ ID NO: 29, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 30. The sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are GYTFTDYY (SEQ ID NO: 13), INPDSGGT (SEQ ID NO: 14), ARGGLLPSSDWSSYYNGMNV (SEQ ID NO: 15), QRVSSF (SEQ ID NO: 16), AA (SEQ ID NO: 17), and QQGYSTPPT (SEQ ID NO: 18), respectively.
[0171] The amino acid sequence of the heavy chain variable region of L3F4 is shown in SEQ ID NO: 31, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 32. The sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are GFTFDNYA (SEQ ID NO: 19), ISWNSGTI (SEQ ID NO: 20), AKVRLRYFDWGSFDY (SEQ ID NO: 21), RSNVLFNT (SEQ ID NO: 22), GT (SEQ ID NO: 23), and SAWDDSLNGYV (SEQ ID NO: 24), respectively.
[0172] Example 3: ELISA verification of Trop2 protein levels
[0173] 1. Construction of PTT5-Trop2 plasmid and protein expression
[0174] The Trop2 antibody screened in Example 2 was constructed into the pTT5 expression vector by homologous recombination, and the correct clone was selected for sequencing verification to prepare the plasmid for transient transfection into 293F cells for protein expression. The size of the Trop2 antibody protein is about 110 kilodaltons. After SDS-PAGE electrophoresis and Coomassie brilliant blue staining, it showed a clear main band. Due to the influence of glycosylation, it was larger than the actual one. The results are as follows Figure 2 shown.
[0175] 2. ELISA detection of Trop2 antibody protein
[0176] The Trop2 antigen produced by ACRO and our company was coated in a 96-well plate at 100 ng / 100 μl / well. The coated plate was placed at 4°C overnight. Control wells without antigen and control wells without primary antibody were set up. CD70 antigen was also set up as a negative control. The next day, the plate was washed three times with 1× PBST (0.05% tween 20), patted dry, and blocked with PBS containing 1% BSA, 200μl / well, incubated at 37℃ for 1h. After blocking, the plate was washed three times with a plate washer, and then our own antibody 100ng / 100μl / well was added, and incubated at 37℃ for 1h; then HRP-FC (1: 500) was diluted in blocking solution, 100μL / well, incubated at 37℃ for 1h, and the plate was washed three times with a plate washer. After washing, TMB color development solution 100μl / well was added, incubated at 37℃ for 15min, and finally StopSolution 100μl / well was added. The OD450 value of the microplate reader was read, and it was found that all Trop2 antibodies had good binding with commercial and our own expressed antigens and did not bind to the control CD70 antigen. Results are shown in Figure 3 .
[0177] Example 4: Preparation of retroviral stock solution containing anti-human Trop2 chimeric antigen receptor element
[0178] 1. Preparation of chimeric antigen receptor targeting human Trop2 antigen
[0179] Gene synthesis or cloning of a chimeric antigen receptor sequence containing a signal peptide, a single-chain antibody scFv against human Trop2 antigen, a hinge region, a transmembrane region and an intracellular signal segment, the structure of which is as follows Figure 4As shown. According to the different scFvs loaded and the intracellular signals, the chimeric antigen receptors were named L2A8-BBz, L3G1-BBz, K2G2-BBz and L3F4-BBz, respectively. Among them, the amino acid and nucleotide sequences of the signal peptide are shown in SEQ ID NOs: 33 and 38, respectively; the amino acid and nucleotide sequences of the CD8 hinge region are shown in SEQ ID NOs: 34 and 39, respectively; the amino acid and nucleotide sequences of the CD8 transmembrane region are shown in SEQ ID NOs: 35 and 40, respectively; the amino acid and nucleotide sequences of the 41BB intracellular co-stimulatory domain are shown in SEQ ID NOs: 36 and 41, respectively; the amino acid and nucleotide sequences of the intracellular CD3z signaling domain are shown in SEQ ID NOs: 37 and 42, respectively; the amino acid sequences of the scFvs of L2A8, L3G1, K2G2 and L3F4 are shown in SEQ ID NOs: 43-46, respectively, and the nucleotide sequences are shown in SEQ ID NOs: 47-50, respectively.
[0180] Using the retrovirus vector MSGV as the backbone vector, retroviral plasmids expressing chimeric antigen receptors of L2A8, L3G1, K2G2 and L3F4 clones were constructed. The clones with correct sequencing were selected, inoculated into 200 ml 2YT medium, shaken overnight, and the large-scale plasmid was completed according to the instructions of the NucleoBond Xtra Maxi EF kit.
[0181] 2. Retroviral packaging
[0182] 1) Use cationic polymer PEI to package retrovirus. The process is as follows:
[0183] 18μl PEI and 3μg of the retroviral packaging master plasmid were diluted with 300μl Opti-MEM (Gibco) without serum respectively; then PEI / Opti-MEM™ was added to the plasmid / Opti-MEM™ mixture, vortexed and mixed, and allowed to stand at room temperature for 10 minutes; the plasmid-PEI complex was added to the pre-plated 293V cells (4E6). The medium was changed 16h after transfection, the first viral supernatant was collected after 48h and placed at 4℃, the second viral supernatant was collected after 72h and combined with the first collection, and filtered with a 0.45μm filter, and dispensed into 1.5ml centrifuge tubes, 1ml / tube, and stored at -80℃ for later use.
[0184] 2) Virus titer detection
[0185] 293T cells were digested and 1E5 cells were plated on TC-treated 24-well plates per well. The packaged virus solution was added to the plated cells at 5μl, 15μl, 45μl, and 135μl per well, respectively, and polybrene was added at a ratio of 1: 2000. The volume of each well was filled to 1ml with the corresponding culture medium. Seal with sealing film and centrifuge at 32°C and 2500rpm for 90min. After 72h, the CAR positive rate was detected by flow cytometry and the virus titer was calculated. The results are shown in Table 1.
[0186] Table 1
[0187] Virus Name Positive rate (%) Virus volume (μl) Number of cells plated Titer (TU / mL) L2A8 20.4 5 1.00E+05 4.08E+06 L3G1 14.8 5 1.00E+05 2.96E+06 K2G2 12.8 45 1.00E+05 2.84E+05 L3F4 16.8 5 1.00E+05 3.36E+06
[0188] Example 5: Trop2 Tonic Signal Detection
[0189] The virus carrying the Trop2 CAR gene was infected into the Jurkat-Nur77-GFP reporter cell line, and the infected cells were transferred to a 37°C, 5% CO2 cell culture incubator for 2-3 days. The infected Jurkat-Nur77-GFP reporter cells, negative control cells 293T, and target cells MDA-MB-231 were taken out for counting, and the corresponding volume was taken according to the number of cells required for the experimental design, and centrifuged at 500g for 5 minutes. The density of all cells was adjusted to 8×10 6 cells / ml, based on 4×10 5 Cells / 50 μl, experimental groups are as follows:
[0190] A. Background group: 50 μL Trop2 CAR-Jurkat-Nur77-GFP cell suspension, add 50 μl R10 complete medium to make up to 100 μl;
[0191] B. Negative control group: 50 μl Trop2 CAR-Jurkat-Nur77-GFP cell suspension, added with 50 μl 293T negative control (NC) cells;
[0192] C. Positive control group: 50 μl Trop2 CAR-Jurkat-Nur77-GFP cells, added with 25 μl 4 μM PMA and 25 μl 4 μM Ionomycin;
[0193] D. Sample group: 50 μl Trop2 CAR-Jurkat-Nur77-GFP cells, added with 50 μl MDA-MB-231 positive target cells.
[0194] The above groups with added samples were placed in a 37℃, 5% CO2 incubator for 4 hours. After incubation, the 96-well plate cells were transferred to a 1.5 ml EP tube, 1 ml PBS was added to wash the cells, 500g, centrifuged for 5 minutes, and the supernatant was discarded. The primary antibody 0.5μg bio-Trop2 / test (homemade) was used for staining at 4℃ in the dark for 30 minutes; the cells were washed after staining; the secondary antibody was prepared in PBS using BV421 Streptavidin (1: 500, Biolegend) and Zombie Red™ Fixable Viability (1: 500, Biolegend), 100 μl for each sample, and stained at 4℃ in the dark for 30 minutes.
[0195] After staining, wash the cells, resuspend them in 100 μl PBS, and test them on the machine. The results are as follows Figure 5 As shown, in the positive control group, all clones had a certain proportion of GFP + Expression, indicating that the experimental system can successfully detect Tonic signals; except for K2G2-CAR Jurkat, other CAR Jurkat background control group and negative control group also have GFP + cells, indicating that other CAR structures have background Tonic signals, while in other CAR Jurkat sample groups, GFP + The cell ratios increased to a certain extent, suggesting that other CARs can be regulated by Trop2 + Target cell-specific activation. However, there was no GFP in the background control group, negative control group, and sample group of K2G2-CAR Jurkat cells. + The positive cell population indicates that although K2G2-CAR has no background Tonic signal, it cannot be detected by Trop2 + Target cells are activated, and it is speculated that the tumor killing function of this structure is poor (the full name of CAR Jurkat is CAR Jurkat-Nur77-GFP).
[0196] Example 6: Preparation of Trop2 CAR-T cells and determination of CAR positivity
[0197] 1. PBMC resuscitation, sorting and activation
[0198] Take a PBMC and resuscitate it after verifying the patient's individual identification code. Use CAR-T culture medium to adjust the cell density to 1~5×10 6PBMCs that have been in remission for 2 hours were gently pipetted, filtered through a 70μm cell mesh, and transferred into a 50ml centrifuge tube. Centrifuged at room temperature, 1500rpm, for 5 minutes, and the supernatant was discarded. The cells were resuspended in an appropriate amount of CAR-T culture medium, and 200μl was taken for counting using NC200 to calculate the viability, CD3 + Cell count, take out appropriate amount of CD3 + Transfer the cell suspension to a 50 ml centrifuge tube and centrifuge at 20°C, 470 g for 5 min. After centrifugation, discard the supernatant and add 3.6 ml DPBS to resuspend the cells. Adjust the density to 1×10 7 After resuspending, transfer to a 5 ml sterile flow cytometry tube. According to the 1:1 ratio of CD3 / CD28 magnetic beads to CD3+ cells, calculate the amount of magnetic beads used: [CD3 + Cell number / 4×10 5 】μl. Wash the magnetic beads with 2ml of DPBS, let it stand on the magnetic rack for 1min, and discard the supernatant. Remove the flow tube from the magnetic rack, resuspend the magnetic beads with cells containing DPBS, and add them to the cell suspension; mix the magnetic beads and cells in a 5ml sterile flow tube, incubate on a rotating mixer, and incubate at room temperature for 30min. After the incubation is completed, place the cells on the magnetic rack for 2min. After removing the negative cells, remove the sterile flow tube from the magnetic rack, resuspend the cells with 1ml CAR-T culture medium, and rinse the tube wall twice with CAR-T culture medium. All are collected and transferred to the same centrifuge tube. Use CAR-T culture medium to adjust the cell density to 1×10 6 / ml, add IL-2 to a final concentration of 300 IU / ml, and culture in a 37˚C, 5% CO2 incubator for two days.
[0199] 2. Viral infection and CAR-T cell preparation
[0200] Add the virus stock solution with MOI=1 to the 24-well plate pre-coated with Retronectin, centrifuge at 32℃, 2000g for 2h. After centrifugation, discard the supernatant and add 1ml of activated T cells (5×10 5 / ml, IL-2 300IU / ml), 32℃, 1000g centrifugation for 10min. After centrifugation, the 24-well plate was transferred to a carbon dioxide incubator at 37℃, 5% CO2 for incubation. The CAR-T cells cultured for 24h were taken out of the incubator, the magnetic beads were removed by magnetic rack, and the cell density was adjusted to 3×10 5 / ml for expanded culture.
[0201] 3. CAR positive rate detection
[0202] The CAR positive rate was detected seven days after CAR-T cell preparation. 1×10 6 Place cells in a 1.5 ml centrifuge tube, centrifuge to remove the culture medium, wash the cells once with 500 μl PBS and resuspend them in 100 μl. Add biotin-labeled Trop2 antigen (0.3 μg / test) and incubate at 4°C for 30 minutes. After incubation, wash the cells once with 1× PBS and add secondary antibodies BV421-SA (1: 500, BioLegend), APC-cy7-CD3 (1: 100, BioLegend), and Zombie Red™ Fixable Viability (1: 500, Biolegend), and incubate at 4°C in the dark for 30 minutes. After incubation, wash the cells with 500 μl PBS, resuspend the cells with 100 μl PBS and detect them on the machine. The results of CAR-T positive rate flow cytometry analysis are as follows. Figure 6 As shown, each cloned CAR protein was expressed in T cells. Except for K2G2, which had a slightly lower positive rate, the positive rates of other CARs were around 60%.
[0203] Example 7: In vitro killing experiment
[0204] The positive target cells MDA-MB-231, MDA-MB-468, HCC1395 overexpressing Trop2 and the negative target cells MDA-MB-231-Trop2KO, MDA-MB-468-Trop2KO and HCC1395 (the expression of Trop2 in each target cell is shown in Figure 7 CAR-T cells were inoculated with Trop2-positive target cells stably expressing firefly luciferase (MDA-MB-231-Luc-GFP, MDA-MB-468-Luc-GFP, HCC1395-Trop2-Luc-GFP, 1×10 target cells) at an effector-target ratio of 3:1. 4 / 100 μl / well), and Trop2 negative control target cells MDA-MB-231-Trop2 KO-Luc-GFP, MDA-MB-468-Trop2 KO-Luc-GFP, HCC1395- Luc-GFP (target cells 1×10 4 / 100μl / well) were co-cultured in a 96-well white plate (Jingan Biotechnology), and a negative control group co-cultured with NT cells and a group without effector cells were set up at the same time. After co-incubation at 37℃ for 19h, the co-incubated cells were centrifuged at 500g for 5min, 90μl of the supernatant was removed, and then the luciferase Bright-Glo TMLuciferase Assay stystem (Promega) reagent 50μl / well. After incubation for ten minutes, the killing efficiency was detected: killing efficiency = (1-fluorescence value of experimental well / fluorescence value of control well) × 100%. The results are as follows Figure 8 , Fig. 9 , Fig.10 and Fig.11 Combined with the expression of Trop2 on each target cell, the short-term killing results showed that K2G2 had almost no killing effect on the high-expression MDA-MB-468 and low-expression MDA-MB-231, which may be related to the low expression level of its CAR and the fact that it was not activated. The CAR structure needs to be optimized according to the characteristics of K2G2 antibody; the killing function of other clones on the target cells with negative knockout of Trop2 was inhibited to a certain extent; on the cell HCC1395 overexpressing Trop2, L3F4 had better killing effect than other clones.
[0205] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A Trop2 binding molecule, characterized in that It is an anti-Trop2 antibody or an antigen-binding fragment thereof, wherein the Trop2 binding molecule comprises a heavy chain variable region and a light chain variable region, and the Trop2 binding molecule has a HCDR1 sequence as shown in SEQ ID NO: 19, a HCDR2 sequence as shown in SEQ ID NO: 20, a HCDR3 sequence as shown in SEQ ID NO: 21, a LCDR1 sequence as shown in SEQ ID NO: 22, a LCDR2 sequence as shown in SEQ ID NO: 23, and a LCDR3 sequence as shown in SEQ ID NO:
24.
2. The Trop2 binding molecule according to claim 1, characterized in that The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:31, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:
32.
3. The Trop2 binding molecule according to claim 1, characterized in that The antibody is at least one of a monoclonal antibody, a humanized antibody, a chimeric antibody, and a bispecific antibody, and the antigen-binding fragment is at least one of Fab, F(ab'), F(ab')2, a single-chain antibody scFv, or a disulfide-bonded Fv (sdFv).
4. A chimeric antigen receptor, characterized in that The chimeric antigen receptor is composed of a signal peptide as shown in SEQ ID NO:33, a Trop2 binding molecule as described in any one of claims 1 to 3, a CD8 hinge region as shown in SEQ ID NO:34, a CD8 transmembrane region as shown in SEQ ID NO:35, a 41BB intracellular co-stimulatory domain as shown in SEQ ID NO:36, and an intracellular CD3z signaling domain as shown in SEQ ID NO:
37.
5. A nucleic acid molecule, characterized in that It has a sequence selected from any of the following: (1) The coding sequence of the Trop2 binding molecule according to any one of claims 1 to 3 or the chimeric antigen receptor according to claim 4; (2) The complementary sequence of (1).
6. A nucleic acid construct, characterized in that It comprises the nucleic acid molecule according to claim 5.
7. The nucleic acid construct according to claim 6, characterized in that The nucleic acid construct is a cloning vector, an expression vector or an integration vector.
8. A host cell, characterized in that Selected from: (1) expressing and / or secreting the Trop2 binding molecule according to any one of claims 1 to 3 or the chimeric antigen receptor according to claim 4; (2) comprising the nucleic acid molecule according to claim 5; and / or (3) Comprising the nucleic acid construct according to claim 6 or 7.
9. The host cell according to claim 8, characterized in that The host cell is an immune effector cell.
10. The host cell according to claim 9, characterized in that The immune effector cells are T cells.
11. A method for producing the Trop2 binding molecule of any one of claims 1 to 3 or the chimeric antigen receptor of claim 4, comprising: Cultivating the host cell according to any one of claims 8 to 10 under conditions suitable for producing the Trop2 binding molecule, and optionally purifying the Trop2 binding molecule or chimeric antigen receptor from the culture.
12. A pharmaceutical composition comprising the Trop2 binding molecule of any one of claims 1 to 3, the chimeric antigen receptor of claim 4, the nucleic acid molecule of claim 5, the nucleic acid construct of claim 6 or 7 or the host cell of any one of claims 8 to 10, and a pharmaceutically acceptable excipient.
13. Use of the Trop2 binding molecule of any one of claims 1 to 3, the chimeric antigen receptor of claim 4, the nucleic acid molecule of claim 5, the nucleic acid construct of claim 6 or 7, or the host cell of any one of claims 8 to 10 in preparing activated T cells, or in preparing a medicament for treating breast cancer.
14. A kit for detecting Trop2, comprising the Trop2 binding molecule according to any one of claims 1 to 3, the nucleic acid molecule according to claim 5, the nucleic acid construct according to claim 6 or 7, or the host cell according to any one of claims 8 to 10.
15. The kit according to claim 14, characterized in that The kit also includes a reagent for detecting the binding of Trop2 to the Trop2 binding molecule.
16. The kit according to claim 15, characterized in that The reagent for detecting binding is a detectable label that can be linked to the Trop2 binding molecule.
Citation Information
Cited By
Anti-Trop2 nano antibody as well as product and application thereof
CN121949555A
